The Optimal Approaches to Oncology Clinical Trial Design and Analysis brings together colleagues in biostatistics, oncology clinical trials, clinical R&D, adaptive trials, oncology drugs and diagnostics, and translational research in an exciting and engaging environment to deliver and develop solutions, industry standards and practical applications for clinical trial design and analysis. Industry leaders, premiere scientists, and clinical research professionals convene, share, and drive forward the science to become a catalyst for progress. Participants over the two-day immersion program walk away with a deeper understanding of the biggest challenges and most promising development in oncology trial design and analysis including:

• Comparison of study endpoint options with a special emphasis on considerations for Progression-free survival (PFS)
  
• Integrated strategies to design the optimal protocol, maximize your opportunity for patient accrual, and effectively select sites to shorten study timelines
  
• Insights into utilizing PK/PD models to support drug development decisions including first-in-man dose range and optimal dosage for later phase studies
  
• Evaluation of various Phase II design options and discuss the pros and cons of randomized designs versus single-arm designs
  
• Overcoming challenges with companion diagnostics and how to address potential regulatory hurdles
  
• Best practices for adaptive trial designs and how to incorporate these trials into
  your drug development plan
  
• Clarity on practical and theoretical issues associated with the use of independent review of scans in oncology trials

This event, along with the entire Target Clinical Trials Series is FREE to clinical research professionals from a pharmaceutical or biotech company.